Oura Acquires AI Primary Care Startup Counsel Health $625M

Oura, the smart ring leader, is making its biggest bet yet on healthcare by acquiring AI-native primary care startup Counsel Health for $625 million. Officially launched on November 10, 2026, the deal transforms Oura from a wearable device maker into an integrated health platform that connects biometric tracking with on-demand medical care. The acquisition comes weeks after Oura postponed its planned $2.2 billion IPO, citing market uncertainty, and signals a strategic pivot toward recurring healthcare revenue.

What Counsel Health Brings to Oura

Counsel Health operates an AI-powered healthcare platform that combines chat-based medical assistance with access to licensed physicians. The service has been integrated into the Oura app since June 2026, allowing users to receive personalized medical advice from Counsel's medical AI and connect with physicians when needed. The platform emphasizes keeping clinicians in the loop for all clinical decisions, differentiating it from fully automated AI diagnostic tools.

Users can handle everything from quick medical questions and prescription refills to reviewing lab results and managing chronic conditions, all without leaving the Oura ecosystem. The integration leverages Oura's continuous biometric data (sleep patterns, heart rate variability, body temperature) to give physicians objective context for more informed clinical decisions.

Strategic Rationale Behind the Deal

The acquisition addresses mounting competitive pressure on Oura from emerging rivals like RingConn and Ultrahuman, which are challenging its dominance in the smart ring market. By expanding into healthcare services, Oura aims to differentiate on care delivery rather than hardware alone. "Oura helps members understand their physiology and, with Counsel, they can take action on their health across a range of needs, from quick questions and prescriptions to lab results, chronic care, and referrals," said Oura CEO Tom Hale.

The move follows a proven playbook in digital health: combine passive monitoring with actionable care. Oura's ring captures physiological signals 24/7, while Counsel provides the clinical expertise to interpret and act on that data. The companies plan to expand across preventative care, acute care, and specialty and chronic care management.

Financial Context and Growth Metrics

Oura disclosed strong financial performance alongside the acquisition announcement. Revenue grew 153% year-over-year to $533 million for the quarter ended September 30, 2026. For fiscal year 2026, Oura generated approximately $1.75 billion in revenue, marking 92% year-over-year growth. The company reached an $11 billion valuation following a $900 million funding round in October 2025.

Counsel Health had raised approximately $36 million in total funding, including a $25 million Series A led by Andreessen Horowitz and GV in 2025. The $625 million purchase price represents a significant premium, reflecting both the strategic value of the technology and the competitive intensity in healthcare AI.

Leadership and Integration Plans

Counsel CEO Muthu Alagappan will join Oura as chief clinical AI officer, bringing the startup's 70 employees with him. "At Counsel, we've built medical AI around trust, safety and responsibility, keeping physicians in the loop for clinical decisions," Alagappan said. "Oura's data gives clinicians objective context, trended biometrics, and member engagement to deliver more informed care."

Following the acquisition, Counsel will continue serving existing and new enterprise partners independently, with the goal of expanding its AI-native care model beyond Oura's direct membership base. The deal is expected to close before the end of 2027, subject to regulatory approvals.

What This Means

Oura's acquisition of Counsel Health represents a critical inflection point for wearable health companies. As hardware margins compress and competition intensifies, the real value lies in the services layer that turns passive data into actionable care. By integrating physician-supervised AI care directly into its platform, Oura is positioning itself as a vertically integrated health company rather than a device maker. The success of this strategy will depend on execution: seamlessly blending biometric insights with clinical workflows, maintaining trust through physician oversight, and scaling care delivery to match its hardware distribution. If successful, the model could redefine how consumers access primary care in an AI-augmented healthcare system.